Michael F. Burgess

CIK 1801745 · Interim Chief Medical Officer · last filed 2023-10-17

Michael F. Burgess is an Interim Chief Medical Officer who has filed 10 SEC Form 4 insider transactions across 3 companies since 2020. The most recent filing, for TSBX, was dated Oct 17, 2023.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

Companies

Total Filings

Lifetime Open-Market Net

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

SYBX price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Exposure by company

latest

OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address

C/O SYNLOGIC, INC.
301 BINNEY STREET, SUITE 402
CAMRIDGE, MA 02142

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
Turnstone Biologics Corp. (TSBX) Delisted	Interim Chief Medical Officer	—	$0.35	—	$0	1	2023-10-17
SYNLOGIC, INC. (SYBX) Delisted	Director	—	$0.69	—	$0	5	2023-06-26
SpringWorks Therapeutics, Inc. (SWTX) Delisted	Head of Research & Development	49,584	$46.99	$2.33M	$0	4	2022-07-20

Recent Filings

10 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2023-10-17	Turnstone Biologics Corp. (TSBX) Delisted	Grant (A)	—	$0	EDGAR
2023-06-26	SYNLOGIC, INC. (SYBX) Delisted	Grant (A)	—	$0	EDGAR
2022-07-20	SpringWorks Therapeutics, Inc. (SWTX) Delisted	Tax (F)	−3,103	-$88.3K	EDGAR
2022-07-05	SpringWorks Therapeutics, Inc. (SWTX) Delisted	Mixed	+9,513	-$52.4K	EDGAR
2022-06-13	SYNLOGIC, INC. (SYBX) Delisted	Grant (A)	—	$0	EDGAR
2022-01-10	SpringWorks Therapeutics, Inc. (SWTX) Delisted	Grant (A)	+15,674	$0	EDGAR
2021-06-14	SYNLOGIC, INC. (SYBX) Delisted	Grant (A)	—	$0	EDGAR
2021-06-01	SpringWorks Therapeutics, Inc. (SWTX) Delisted	Grant (A)	+27,500	$0	EDGAR
2020-06-08	SYNLOGIC, INC. (SYBX) Delisted	Grant (A)	—	$0	EDGAR
2020-02-04	SYNLOGIC, INC. (SYBX) Delisted	Grant (A)	—	$0	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.